Behavioral and Integrative Treatment Development Program (R34)

archived

Purpose. The purpose of this R34 Funding Opportunity Announcement (FOA) is to advance evidence-based treatment research through 1) the development, manualization, standardization, early-stage efficacy and/or pilot testing of novel or adapted treatments and/or interventions (i.e. Stage 1 treatment research, see below), 2) the refinement, modification, adaptation and/or pilot testing of interventions with demonstrated efficacy for use in broader scale efficacy or effectiveness trials, or 3) novel treatment research that requires preliminary testing or development. It is expected that research conducted via this R34 mechanism will primarily consist of Stage I treatment development research that will provide feasibility, tolerability, and acceptability information and/or pilot data for larger scale Stage II or Stage III behavioral and integrative treatment studies. This FOA seeks to support research, as described above, within the domains of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (3) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (4) interventions to treat chronic pain. Mechanism of Support. This FOA will use the R34 mechanism and runs in parallel with FOAs of identical scientific scope, PA-10-012, which encourages applications under the Research Project Grant (R01) mechanism, and PA-10-011 which encourages applications under the NIH Small Research Grant (R03) mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

High